Xiaochen Yu
NHC Key Laboratory Of Hormones And Development, Tianjin Key Laboratory Of Metabolic Diseases
Tianjin, China
Tianjin, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Corrigendum: Empagliflozin alleviates hepatic steatosis by activating the AMPK-TET2-autophagy pathway in vivo and in vitro.
Journal: Frontiers in pharmacology
Published: August 09, 2024
Integrin β6 mediates epithelial-mesenchymal transition in diabetic kidney disease.
Journal: Molecular and cellular endocrinology
Published: February 17, 2023
Empagliflozin Inhibits Hepatic Gluconeogenesis and Increases Glycogen Synthesis by AMPK/CREB/GSK3β Signalling Pathway.
Journal: Frontiers in physiology
Published: November 18, 2021
Empagliflozin Induces White Adipocyte Browning and Modulates Mitochondrial Dynamics in KK Cg-Ay/J Mice and Mouse Adipocytes.
Journal: Frontiers in physiology
Published: July 21, 2021
Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro.
Journal: Frontiers in pharmacology
Published: October 27, 2020
Empagliflozin improves diabetic renal tubular injury by alleviating mitochondrial fission via AMPK/SP1/PGAM5 pathway.
Journal: Metabolism: clinical and experimental
Published: April 19, 2020
Urinary miR-3137 and miR-4270 as potential biomarkers for diabetic kidney disease.
Journal: Journal of clinical laboratory analysis
Published: February 12, 2020
Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice.
Journal: Clinical science (London, England : 1979)
Published: June 03, 2019
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
Journal: Cardiovascular diabetology
Published: November 12, 2018
Pancreatic kallikrein protects against diabetic retinopathy in KK Cg-Ay/J and high-fat diet/streptozotocin-induced mouse models of type 2 diabetes.
Journal: Diabetologia
Published: September 12, 2018
Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta-analysis.
Journal: Diabetes/metabolism research and reviews
Published: August 26, 2018
Showing 1-11 of 11
Last Updated: 09/26/2026